Stocklytics Platform
Corcept Therapeutics
CORT88
$54.85arrow_drop_down0.32%-$0.17
NASDAQ - As of Mar 14, 1:50 AM EDT Market Closed
High Quality
High Growth
CORT88

$54.85

arrow_drop_down0.32%

Performance History

arrow_drop_up136.11%

(+$31.62 )

Stocklytics logo
Key Stats
Open$55.29
Prev. Close$55.00
EPS1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$5.78B
PE Ratio44.59
LOWHIGH
Day Range54.16
57.07
52 Week Range20.84
76.21
Ratios
P/B Ratio9.40
Revenue$675.04M
Operating M. %13.89%
Earnings$141.20M
Earnings Growth %33.04%
EBITDA Margin %20.41%
ROE %23.81%
EPS1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Stocklytics logo

Period: Next 12 Months

•

Predicted: just now

info

Analyzed by 22 Wall Street experts, Corcept Therapeutics 's 12-month projections average at $31.00, spanning from a high of $42.00 to a low of $22.00. This signifies an -43.48% shift from the current price of $54.85.

Analyst Ratings

Buy

Buy
4
100.00%
Hold
0
0.00%
Sell
0
0.00%
•Ratings from: March•

Last updated: just now

•Total: 4
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

Eli Lilly & Co
LLY84
Price$801.65
Perf. (24h)arrow_drop_down2.37%-$19.52
Market Cap$720.01B
UnitedHealth Group
UNH69
Price$481.52
Perf. (24h)arrow_drop_up0.08%$0.40
Market Cap$444.64B
Johnson & Johnson
JNJ61
Price$162.99
Perf. (24h)arrow_drop_up0.08%$0.14
Market Cap$397.30B
AbbVie
ABBV67
Price$211.55
Perf. (24h)arrow_drop_down0.24%-$0.50
Market Cap$373.46B

About Corcept Therapeutics (CORT)

Corcept Therapeutics Inc (CORT) is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company focuses on discovering and developing small molecule drugs that selectively modulate the effects of cortisol. Corcept's lead product, Korlym, is an oral medication that is approved for the treatment of hyperglycemia in patients with endogenous Cushing's syndrome. The company is also conducting clinical trials to evaluate the use of Korlym in the treatment of various types of cancer, including ovarian, lung, and pancreatic cancer.
In terms of stock performance, Corcept Therapeutics Inc has had a relatively stable history. Over the past five years, the stock price has fluctuated between a low of $7.50 and a high of $25.00. Currently, the stock is trading around $15.00. The market capitalization of Corcept Therapeutics Inc is approximately $1.5 billion. The company has a PEG ratio of 1.42, indicating that the stock may be slightly overvalued compared to its industry peers. However, it is important to note that the biopharmaceutical industry as a whole tends to have higher valuations due to the high-risk nature of drug development. Corcept Therapeutics Inc is also trading below its 52-week high of $24.00, suggesting that there may be potential for price appreciation in the future.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joseph K. Belanoff M.D.
Headquarters
Menlo Park
Employees
299
Exchange
NASDAQ
add Corcept Therapeutics to watchlist

Keep an eye on Corcept Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Corcept Therapeutics 's (CORT) price per share?

The current price per share for Corcept Therapeutics (CORT) is $54.85. The stock has seen a price change of -$0.18 recently, indicating a -0.33% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Corcept Therapeutics (CORT)?

For Corcept Therapeutics (CORT), the 52-week high is $76.21, which is 38.94% from the current price. The 52-week low is $20.84, the current price is 163.2% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Corcept Therapeutics (CORT) a growth stock?

Corcept Therapeutics (CORT) has shown an average price growth of -1.65% over the past three years. It has received a score of 88 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Corcept Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Corcept Therapeutics (CORT) stock price performance year to date (YTD)?

As of the latest data, Corcept Therapeutics (CORT) has a year-to-date price change of 8.85%. Over the past month, the stock has experienced a price change of -25.49%. Over the last three months, the change has been -0.99%. Over the past six months, the figure is 43.93%. Looking at a longer horizon, the five-year price change stands at 407.87%.
help

Is Corcept Therapeutics (CORT) a profitable company?

Corcept Therapeutics (CORT) has a net income of $141.21M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 13.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $675.04M, with a revenue growth rate of 39.94%, providing insight into the company's sales performance and growth. The gross profit is $664.16M. Operating income is noted at $136.95M. Furthermore, the EBITDA is $138.29M.
help

What is the market capitalization of Corcept Therapeutics (CORT)?

Corcept Therapeutics (CORT) has a market capitalization of $5.79B. The average daily trading volume is 54.78, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level